Clinical Trials Logo

Clinical Trial Summary

15 patients with moderate to severe allergic rhinitis against grass were recruited and enrolled in the study. They received three open label intralympatic grass allergen injections with the dose 1000 SQ-U each and with one month interval. The next year the patients were randomized double blind to an active or placebo booster injection of 1000 SQ-U before the pollen season. Grass specific IgG4 levels were measured before and at various time ponts after treatment.


Clinical Trial Description

The purpose of the study is to evaluate whether intralymphatic administration of AIT is a safe and effective treatment for patients with pollen-induced allergic rhinitis. The long term goal is to provide a base for a more efficient administration of ASIT, which will reduce both the dose necessary and the number of clinic visits associated with the conventional subcutaneous ASIT.

The aim of the present substudy is to evaluate if a randomized preseasonal ILIT booster, after three open label ILIT injections, can increase the allergen specific IgG4 antibodies, and if the IgG4 increase can be correlated to clinical effect characterized with seasonal questionnaires.

The first part of the study is completed and published (PMID: 23374268) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04210193
Study type Interventional
Source Karolinska Institutet
Contact
Status Completed
Phase Phase 2/Phase 3
Start date April 25, 2014
Completion date December 1, 2019

See also
  Status Clinical Trial Phase
Completed NCT03290248 - Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis Phase 1/Phase 2
Completed NCT06104293 - Determination of Grass Pollen Allergen Concentration Inducing Rhinoconjunctivitis Symptoms in Subjects Allergic to Grass Pollen in ALYATEC Allergen Exposure Chamber N/A
Completed NCT04878237 - Kinetics of Nasal Cytokine Responses to Mechanical Stimulation N/A
Completed NCT04802616 - The Influence of Nonspecific Immunostimulation on Changes in the Concentration of iNKT Cells Phase 3
Active, not recruiting NCT05297760 - Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract Phase 1/Phase 2
Recruiting NCT06061848 - Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT Phase 2/Phase 3
Not yet recruiting NCT04700852 - Efficacy of Puressentiel Protective Nasal Spray in Allergic Rhinitis N/A
Completed NCT05037955 - ILIT: Follow-up of Rhinitis Quality of Life
Active, not recruiting NCT05191186 - Documentation of Efficacy of Intralymphatic Allergen Immunotherapy Phase 3
Completed NCT01953471 - Prospective Observational Study for Determination of Minimal Clinically Important Difference of Allergic Rhinitis Symptoms Due to Grass Pollen (Equinoxe 2) N/A